News Release
Applied UV's Devices Effective Against Dangerous Pathogen Candida Auris As CDC Warns Of Rapid Spread In US Healthcare Facilities
Applied UV, Inc.
Applied UV, Inc. (NASDAQ: AUVI) recently announced that the Center of Disease Control (CDC) has warned that Candida Auris (C. auris) is spreading rapidly through U.S. healthcare facilities. As the company previously announced, the Sterilumen family of disinfection devices was independently tested by ResInnova Laboratories (an independent microbiology testing laboratory specializing in antimicrobial technologies) who confirmed that the Company’s devices kill C.auris on sink handles, achieving a log2 kill in just fifteen minutes of operation. Applied UV’s recently acquired Puro UV completed independent lab testing commissioned by Violet Defense ™, the UV technology provider powering Puro’s Helo products, and performed at an EPA and FDA GLP-compliant, ISO 17025 Accredited Testing Laboratory. Testing determined that Puro UV disinfecting fixtures are effective at killing the C. auris fungus. Sterilumen’s complete family of air and surface disinfection devices including Airocide® Air Purification System, a proprietary airborne pathogen killing technology originally developed for use by NASA and listed as a FDA Class II Medical Device that uses a patented combination of UVC and a proprietary, titanium dioxide based photocatalyst, kills the emerging multi-drug resistant fungus, Candida auris (“C. auris”) as well as its surface disinfection platform Lumicide. Additionally, independent research previously conducted demonstrated that Airocide® also kills MRSA (methicillin-resistant Staphylococcus aureus). Applied UV‘s patented LumiCide Surface and Drain UVC Disinfecting Systems is currently installed within the world renowned Mt. Sinai Medical Center Morningside in a trial, the results of which are expected to be published late in Q3 2023 which would further validate the previously obtained independent results conducted by ResInnova Laboratories. This validation could facilitate the adoption of the Company’s LumiCide Surface and Drain disinfection solutions throughout healthcare facilities globally. Mount Sinai Morningside, formerly known as Mount Sinai St. Luke's, is a teaching hospital located in the Morningside Heights neighborhood of Manhattan in New York City. Mount Sinai Morningside is affiliated with the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, a nonprofit hospital system formed by the merger of Continuum Health Partners and the Mount Sinai Medical Center in September 2013. It provides general medical and surgical facilities, ambulatory care, and a Level 2 Trauma Center, verified by the American College of Surgeons. It operates 21 clinics and as of 2020, is nationally ranked by U.S. News & World Report. Candida auris is an emerging fungal pathogen that presents a serious global health threat. It enters the body through the skin and infects the bloodstream, central nervous system, and multiple internal organs. It has been identified as being multiple drug resistant, and the disease is particularly pernicious in patients with weakened immune systems, which is why it is so problematic in hospitals and long-term care facilities. “CDC“ currently considers Candidiasis as one of the most significant infectious diseases in the world today. Applied UV’s LumiCide Disinfection System product line has the following attributes: Focus on the sink area and drain. Focuses on pathogens that accumulate on the sink area, including handles, faucets and backsplash and in the drain. UVC LED Pathogen Destruction. Destroys 4 logs (99.99%) some of the most dangerous pathogens like COVID 19, MERSA C’diff, in the bathroom vanity/sink area with at least two hours of continuous use. Automatic operation. Built-in programmable controller that ensures operation for the full required daily time and is not dependent on manual operation. Continuous operation. Works in cycles of two hours on and four hours off, except for the disinfecting drain which is on 15 minutes every hour. The timing protocol is managed by a programmable controller and a motion detector enclosed within each device and works while the room is still occupied and while the bathroom is not in use, therefore, continuously disinfecting an area of ongoing high contamination. Safety. Built-in motion detector and sensor automatically shuts off the UVC light when anyone enters the room eliminating any concern over UV safety. Once there is no movement in the room for 10 minutes the UVC light comes back on to restart and continue its cycle. Removable UVC LED panel. The UVC LEDs are installed via a removable panel, leading to ease of replacement or upgrade. Ease of Installation. The unit is easy to install and uses standard electrical wiring. IOT connectivity. IOT connectivity uses Wi-Fi and RF technology that enables continuous transmission of use and functionality data over the Internet for collection and analysis. Applied UV’s internal research and research provided by the CDC estimates that each year about one in 25 U.S. hospital patients (approximately 1.4 million people) are diagnosed with at least one infection related to hospital care alone and additional infections occur in other healthcare settings. Approximately 900,000 Americans die each year due to complications associated with Hospital Acquired Infections (“HAI”). Many HAI’s are caused by the most urgent and serious antibiotic-resistant (AR) bacteria and my lead to sepsis or death. According to NIH, Healthcare-associated infections are known to increase the length of stay, healthcare costs, and mortality. Each year the top five healthcare-associated infections result in about $9.8 billion in costs. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/
March 24, 2023 09:25 AM Eastern Daylight Time
News Release
